This is a terrible HPLC run

Here we go. First time disclosure!#AACR22

Novel Drugs at AACR | drughunter.com/new-drug-candi… An oral BRD9 degrader and a PDE3A-SLFN12 molecular glue clinical candidate among today’s disclosures at AACR. Thanks to reviewer Julien Lefranc for sharing his notes with everyone! We’ll be updating the tally live on the site tomorrow

New lab #preprint! HLB-0532259: A chemical degrader of N-Myc that targets Aurora kinase A. Want to hear the development story in-person? Jian Tang from the #HarkiLab will present at #AACR22 today - 3:05 pm, New Orleans Theater B. University of Minnesota Medicinal Chemistry Masonic Cancer Center, University of Minnesota biorxiv.org/content/10.110…

Really cool new preprint from Dan Harki University of Minnesota Medicinal Chemistry: Aurora kinase A #PROTACs potently promote the concurrent degradation of Aurora A and N-Myc!

And that's it for AACR New Drugs Session! All 10 small molecules listed here: drughunter.com/new-drug-candi…

Beautiful work on a novel Aurora kinase A & N-Myc degrader from Dan Harki lab is just published in BioRxiv. I had the pleasure of building molecular models of this degrader and working with an amazing team. #protac biorxiv.org/content/10.110…

Read other insightful articles reviewing the current toolbox for #APOBEC drug discovery Katherine Jones @HarrisLabUMN Dan Harki UMN Department of Chemistry, iPSC technologies for #epileptic encephalopathy therapeutics discovery Dina Simkin Northwestern Feinberg School of Medicine, circulating tumor cells in precision medicine 2/5

I am looking to fill at least 3 postdoctoral positions in the #HarkiLab University of Minnesota Medicinal Chemistry. Check out the team and projects at harki.umn.edu.

Big congrats!🎉 Katherine Jones

Of all the **things** covid-related, being asked to use our #BeyondShielding image as the cover for *this* textbook... has been the biggest honor (& hardest secret to keep so long!) 🤓🥰 Grateful for the #glycotime community & support ♥️ & for Lorenzo Casalino's stunning art! 🤩

Hellooo tweeps! Hiring (all levels) in sunny La Jolla - projects working on targets in COVID, MD simulations with heavy emphasis on drug disco & design DM me if interested or email 🤓

Dr. Dan Harki will serve as the co-investigator and dep. dir. of the Med. Chem. and Drug Metabolism & Pharmacokinectics Core for the Midwest Antiviral Drug Discovery Center which will develop antiviral drugs for pandemic-level viruses. Read more > pharmacy.umn.edu/news-and-event…

Had a blast week attending my first #BioorganicGRC and very honored to receive an outstanding poster award. Great science, great conversations, and most of all, great people! Many thanks to the organizers and the staff on site for the supportive and inclusive environment!

Very cool work led by Erik Faber MD PhD in the Gunda I. Georg lab on the discovery of allosteric CDK2 inhibitors. Kinase fans must read!

PAPER OUT !! 🎉🥂🍾 @nature nature.com/articles/s4158… Viral restrictor APOBEC3A is a major cause of mutational signatures found in >50% of cancers + more, Tweetorial👇 With John Maciejowski Via WGS/251 cancer clones (available!) Broad Institute Memorial Sloan Kettering Cancer Center Wellcome Sanger Institute

So excited to share that I successfully defended my PhD thesis yesterday! Many thank to the #harkilab members for the lovely cake decorations!

Our male non-hormonal contraceptive made it to #1 on the BBC Science Focus list of "The 19 most mind-blowing science stories of 2022"!!

Congratulations to all co-authors. DOI 10.1038/s41467-023-38732-x

The Medicinal Chemistry Department celebrates and honors Dr. Phillip S. Portoghese as he retires from the University after 62 years of exemplary teaching, research, and service. Please see the full announcement here: pharmacy.umn.edu/news/retiremen…